The Mitogen-activated protein kinase (MAPK) pathway represents the signaling pathway most frequently dysregulated in melanoma and many inhibitors against this cascade have been developed at preclinical and clinical levels [12,13]. The gene discussed is WNK2; the disease is melanoma.